U.S. researchers found that Novartis' cancer drug Gleevec has the ability to block the beta-amyloid protein that triggers development of brain-damaging plaques in mice with Alzheimer's disease. "The development of compounds that work like Gleevec, but have the ability to pass the blood-brain barrier and target gamma-secretase activating protein could revolutionize the treatment of this disease," the lead researcher said.

Full Story:

Related Summaries